Bloom Burton Issues Negative Forecast for BioSyent Earnings

Key Points

• Bloom Burton has revised its FY2025 earnings per share estimate for BioSyent to $0.74, down from $0.75, while the current consensus estimate stands at $0.69.
• BioSyent announced a quarterly dividend of $0.05 per share, with a yield of 1.7%, scheduled for payment on September 15th.
• As of Wednesday, BioSyent's shares are trading at C$12.05, with a market capitalization of C$137.82 million and a P/E ratio of 19.56.

BioSyent Inc. (CVE:RX - Free Report) - Research analysts at Bloom Burton reduced their FY2025 earnings per share (EPS) estimates for shares of BioSyent in a report released on Monday, August 25th. Bloom Burton analyst D. Martin now expects that the company will post earnings of $0.74 per share for the year, down from their previous estimate of $0.75. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share.

BioSyent Price Performance

Shares of RX traded down C$0.04 on Wednesday, reaching C$12.07. The stock had a trading volume of 9,415 shares, compared to its average volume of 4,185. The firm has a market capitalization of C$135.86 million, a PE ratio of 16.99 and a beta of 0.45. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The firm has a 50-day moving average of C$11.63 and a 200 day moving average of C$11.28. BioSyent has a twelve month low of C$9.20 and a twelve month high of C$12.40.

BioSyent Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 1.7%. BioSyent's dividend payout ratio is currently 26.76%.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.